GP 1447

Drug Profile

GP 1447

Latest Information Update: 12 Jun 2000

Price : $50

At a glance

  • Originator Grelan Pharmaceutical
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Aldehyde reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Diabetic complications

Most Recent Events

  • 12 Jun 2000 No-Development-Reported for Diabetic complications in Japan (Unknown route)
  • 02 Oct 1998 A study has been added to the pharmacodynamics section
  • 29 Apr 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top